Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05944562 · ClinicalTrials.gov registry record · Phase 1
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
A Phase 1 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05944562 is a Phase 1 study of Mycosis Fungoides and Sezary Syndrome that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 24 participants, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05944562, a Phase 1 study of Mycosis Fungoides and Sezary Syndrome, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypotheses of this study are that single agent DZR123 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, DZR123 will demonstrate efficacy and be worth of further study.
Conditions Studied
Interventions
- DRUG Tulmimetostat
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-09 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05944562
The ClinicalTrials.gov registry entry for NCT05944562 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (85% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 1 intervention - of which Tulmimetostat is the first listed.
NCT05944562 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05944562 about?
NCT05944562 is a clinical study titled "Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome". The hypotheses of this study are that single agent DZR123 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, DZR123 will demonstrate efficacy and be worth o...
What is the current status of trial NCT05944562?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-01-09. Estimated completion is 2029-01-31.
What conditions does trial NCT05944562 study?
This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome.
What interventions are being tested in trial NCT05944562?
The interventions under investigation include: Tulmimetostat (DRUG).
Who is sponsoring clinical trial NCT05944562?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05944562 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
COMPLETED · Phase 1
-
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.